Background Only 20 percent of renal and bladder cancer patients will show a significant
response to immune checkpoint inhibitor (ICI) therapy, and no test currently available …

Immunotherapy with immune checkpoint inhibitors can induce durable clinical responses in
different human malignancies but the number of responding patients remains globally …

Immune checkpoint inhibitor therapy has changed clinical practice for patients with different
cancers, since these agents have demonstrated a significant improvement of overall survival …

Developing and validating model systems for immuno-oncology: Cancer Cell Skip to Main
Content Skip to Main Menu Advertisement Cancer Cell This journal offers authors two options …

In the past decade, immune checkpoint inhibitors (ICI) have proven to be tremendously
effective for a subset of cancer patients. However, it is difficult to predict the response of …

The tumor immune microenvironment (TIME) is likely an important determinant of sensitivity
to immune checkpoint inhibitor (ICI) treatment. However, a comprehensive analysis covering …

The immune checkpoint blockade represents a revolution in cancer therapy, with the
potential to increase survival for many patients for whom current treatments are not effective …

In spite of impressive response rates in multiple cancer types, immune checkpoint inhibitors
(ICIs) are active in only a minority of patients. Alternative strategies currently aim to combine …

Cancer incidence and mortality are increasing globally. Cancer immunotherapies, such as
immune checkpoint inhibitors and adoptive cell therapy, have been recognized as a …

Simple Summary The future of cancer immunotherapy relies on a combination of individually
targeted therapies. However, a lot of experiments are needed to define the most effective …